Product Name |
Code |
Species Reactivity |
Application |
Size |
---|---|---|---|---|
GIPR Recombinant Monoclonal Antibody |
CSB-RA009438MA1HU | Human, Macaca fascicularis | ELISA | 100μl/50μl |
BTLA Recombinant Monoclonal Antibody |
CSB-RA773799MA1HU | Human | ELISA, FC | 100μl/50μl |
ACVRL1 Recombinant Monoclonal Antibody |
CSB-RA001262MA1HU | Human | ELISA | 100μl/50μl |
CD81 Recombinant Monoclonal Antibody |
CSB-RA004960MA1HU | Human | ELISA | 100μl/50μl |
CCR6 Recombinant Monoclonal Antibody |
CSB-RA004845MA1HU | Human | ELISA | 100μl/50μl |
GIPR Recombinant Monoclonal Antibody |
CSB-RA009438MA2HU | Human | ELISA, WB | 100μl/50μl |
ROBO1 Recombinant Monoclonal Antibody |
CSB-RA896760MA1HU | Human | ELISA, IHC, IF, FC | 100μl/50μl |
SOD1 Recombinant Monoclonal Antibody |
CSB-RA022397MA1HU | Human | ELISA, IF, FC | 100μl/50μl |
SLAMF7 Recombinant Monoclonal Antibody |
CSB-RA021369MA1HU | Human | ELISA, IHC, FC | 100μl/50μl |
UBC Recombinant Monoclonal Antibody |
CSB-RA316735MA1HU | Human | ELISA, FC | 100μl/50μl |
C5 Recombinant Monoclonal Antibody |
CSB-RA003995MA1HU | Human | ELISA, FC | 100μl/50μl |
PRDX2 Recombinant Monoclonal Antibody |
CSB-RA339235MA1HU | Human | ELISA, IHC, FC | 100μl/50μl |
SNCG Recombinant Monoclonal Antibody |
CSB-RA021915MA1HU | Human | ELISA, IHC, FC | 100μl/50μl |
CALR Recombinant Monoclonal Antibody |
CSB-RA004458MA1HU | Human, Mouse | ELISA, WB, IHC, IF, FC | 100μl/50μl |
GIPR Recombinant Monoclonal Antibody |
CSB-RA009438MA1MOV | Macaca fascicularis, Human | ELISA, WB | 100μl/50μl |
ANXA4 Recombinant Monoclonal Antibody |
CSB-RA001845MA1HU | Human, Mouse | ELISA, WB, FC | 100μl/50μl |
ANXA1 Recombinant Monoclonal Antibody |
CSB-RA001836MA1HU | Human | ELISA, IHC, FC | 100μl/50μl |
CTLA4 Recombinant Monoclonal Antibody |
CSB-RA006163MA1HU | Human, Mouse | ELISA, WB, IF, FC | 100μl/50μl |
CTSL Recombinant Monoclonal Antibody |
CSB-RA006193MA1HU | Human | ELISA, IHC, IF | 100μl/50μl |
NTRK2 Recombinant Monoclonal Antibody |
CSB-RA619082MA1HU | Human | ELISA, IF | 100μl/50μl |
CD40 Recombinant Monoclonal Antibody |
CSB-RA004936MA1HU | Human | ELISA, IF, FC | 100μl/50μl |
ITGAV Recombinant Monoclonal Antibody |
CSB-RA011877MA1HU | Human | ELISA, IF, FC | 100μl/50μl |
GPC3 Recombinant Monoclonal Antibody |
CSB-RA009705MA1HU | Human | ELISA, FC | 100μl/50μl |
FSCN1 Recombinant Monoclonal Antibody |
CSB-RA619084MA1HU | Human | ELISA, IHC | 100μl/50μl |
IGF1R Recombinant Monoclonal Antibody |
CSB-RA011087MA1HU | Human | ELISA, FC | 100μl/50μl |
LGALS1 Recombinant Monoclonal Antibody |
CSB-RA012882MA1HU | Human | ELISA, FC | 100μl/50μl |
CD3E Recombinant Monoclonal Antibody |
CSB-RA004931MA1HU | Human | ELISA, FC | 100μl/50μl |
XPNPEP1 Recombinant Monoclonal Antibody |
CSB-RA878859MA1HU | Human | ELISA, IHC, FC | 100μl/50μl |
HSPB1 Recombinant Monoclonal Antibody |
CSB-RA010833MA1HU | Human | ELISA, IHC, FC | 100μl/50μl |
GPNMB Recombinant Monoclonal Antibody |
CSB-RA622928MA1HU | Human | ELISA, FC | 100μl/50μl |
GJB2 Recombinant Monoclonal Antibody |
CSB-RA009452MA1HU | Human | ELISA, IHC, FC | 100μl/50μl |
GSN Recombinant Monoclonal Antibody |
CSB-RA009965MA1HU | Human | ELISA, WB, IF | 100μl/50μl |
UBE2C Recombinant Monoclonal Antibody |
CSB-RA025440MA1HU | Human | ELISA, IHC, FC | 100μl/50μl |
HIF1A Recombinant Monoclonal Antibody |
CSB-RA624113MA1HU | Human | ELISA, IF, FC | 100μl/50μl |
VIM Recombinant Monoclonal Antibody |
CSB-RA025857MA1HU | Human | ELISA, IHC, IF | 100μl/50μl |
ADAM10 Recombinant Monoclonal Antibody |
CSB-RA001273MA1HU | Human | ELISA, FC | 100μl/50μl |
ITGB4 Recombinant Monoclonal Antibody |
CSB-RA011887MA1HU | Human | ELISA, FC | 100μl/50μl |
CD44 Recombinant Monoclonal Antibody |
CSB-RA004938MA1HU | Human | ELISA, FC | 100μl/50μl |
PCNA Recombinant Monoclonal Antibody |
CSB-RA017621MA1HU | Human | ELISA, FC | 100μl/50μl |
CD274 Recombinant Monoclonal Antibody |
CSB-RA878942MA1HU | Human | ELISA, IHC, FC | 100μl/50μl |
MAPT Recombinant Monoclonal Antibody |
CSB-RA013481MA1HU | Human | ELISA, FC | 100μl/50μl |
PDPN Recombinant Monoclonal Antibody |
CSB-RA017739MA1HU | Human, Mouse | ELISA, WB, IHC, FC | 100μl/50μl |
MET Recombinant Monoclonal Antibody |
CSB-RA013714MA1HU | Human | ELISA, IF, FC | 100μl/50μl |
FN1 Recombinant Monoclonal Antibody |
CSB-RA008759MA1HU | Human | ELISA, FC | 100μl/50μl |
EDAR Recombinant Monoclonal Antibody |
CSB-RA892357MA1HU | Human | ELISA, IHC | 100μl/50μl |
EPCAM Recombinant Monoclonal Antibody |
CSB-RA007717MA1HU | Human | ELISA, IHC, FC | 100μl/50μl |
CTNNB1 Recombinant Monoclonal Antibody |
CSB-RA006169MA1HU | Human | ELISA, IHC, IF, FC | 100μl/50μl |
PECAM1 Recombinant Monoclonal Antibody |
CSB-RA017767MA1HU | Human, Mouse | ELISA, WB, FC | 100μl/50μl |
SNRPD1 Recombinant Monoclonal Antibody |
CSB-RA022332MA1HU | Human | ELISA, IHC, IF, FC | 100μl/50μl |
TK1 Recombinant Monoclonal Antibody |
CSB-RA023577MA1HU | Human | ELISA, IHC | 100μl/50μl |
A stable and highly specific antibody plays an important role in obtaining real and repeatable experimental results. It is a big headache if the antibody used in the experiment does not work. And what's even worse is that you use the antibodies to repeat the same experiment but get inconsistent results.
It is estimated that the annual loss in research funding due to the use of antibodies without enough validation is about $ 800 million worldwide. At the same time, it has caused countless experimental failures, and a waste of precious samples and researchers'youth.
Nowadays, the antibody validations information provided by antibody manufacturers and academic articles is very helpful for you to select high-quality antibodies. However, there is still an inevitable problem: whether it is polyclonal antibodies extracted from animal serum or monoclonal antibodies produced by hybridomas, there are more or fewer differences between batches. And recombinant antibodies may finally solve this problem.
Recombinant antibodies refers to the application of molecular cloning and gene mutation technology to transform a gene coding sequence of an antibody to produce superior performance of antibodies, also known as genetically engineered antibodies. Comparing with monoclonal antibodies generated in vivo of living animals through hybridoma technology, recombinant antibodies are a type of monoclonal antibodies which are produced in vitro by using synthetic genes.
In recent years, the use of recombinant antibodies is becoming increasingly wider and deeper in both therapeutics and diagnostics. With significant advantages over conventional antibodies, recombinant antibodies become more and more favored. The most important point is that recombinant antibodies can maximize the humanization to solve the heterogeneity between different species.
Generally speaking, recombinant antibodies can be divided into three classes, including chimeric antibody, humanized antibody, fully humanized antibody and small molecular antibody.
Compared with traditional antibodies, recombinant antibodies have the advantages of being irresistible, which is one of the reasons for their gradually emerging. Here, we present the advantages one by one as follows:
Because recombinant antibodies have these unprecedented advantages, recombinant antibodies fulfill a large spectrum of functions spanning from research to diagnosis and treatment therapies for various diseases. Their specificity and low immunogenicity make them a great alternative to traditional forms of treatment, increasing the accuracy of targeting specific molecules and avoiding adverse side effects.
Additionally, for recombinant antibodies production, it follows principally similar workflow. Generally, it consists of five steps: the construction of antibody gene library, phage display, the separation of antibodies, the modification of the isolated antibodies, and the scaling up of the production of selected antibodies in the cell culture expression system.
Although the processes of recombinant antibodies production are same as workflow, we need to recognize that there are several obstacles to the production of recombinant antibodies, such as lower antibody production, and highly trained and experienced technicians. Due to the complexity and intensive high technology of recombinant antibody production, most scientists need to obtain them from outsourcing companies.
Read the article, The Overview of Recombinant Antibody, for more information.
S Antibody referenced in "A magneto-optical biochip for rapid assay based on the Cotton–Mouton effect of γ-Fe2O3@ Au core/shell nanoparticles", Journal of nanobiotechnology, 2021.
SARS-CoV-2 Spike RBD Nanobody referenced in "Potent antiviral activity of Agrimonia pilosa, Galla rhois, and their components against SARS-CoV-2", Bioorganic & Medicinal Chemistry, 2021.
HIF1A Antibody, CASP3 Antibody referenced in "PESV represses non-small cell lung cancer cell malignancy through circ_0016760 under hypoxia", Cancer cell international, 2021.
Phospho-ERN1 (S724) Antibody referenced in "The ER stress sensor inositol-requiring enzyme 1α in Kupffer cells promotes hepatic ischemia-reperfusion injury", Journal of Biological Chemistry, 2021.
CDK4 Antibody and CDK6 Antibody referenced in "Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells Via Forkhead Box M1 Suppression", Journal of Cancer, 2021.
BIRC5 Antibody referenced in "LTBP4 Inhibits the Proliferation and Metastasis in Melanoma by Activating Hippo-YAP Signaling", Research Square, 2020.